Staidson(Beijing) BioPharmaceuticals Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established in August 2002 and listed on the Shenzhen Stock Exchange Growth Enterprise Board in April 2011. The stock code is 300204 Shutaishen. The company's main business is the research and development, production, and marketing of innovative drugs with independent intellectual property rights. It belongs to the category of "C27 Pharmaceutical Manufacturing Industry" in the industry classification of listed companies by the China Securities Regulatory Commission. It is a full industry chain innovative biopharmaceutical enterprise that covers early exploratory research, drug discovery, process development and pilot scale up, preclinical biological evaluation, clinical development, drug production, and commercialization. It has complete research and development The production and marketing system is a national level high-tech enterprise. The company is committed to research, development, production and sales of therapeutic drugs whose clinical needs have not been met, mainly including protein drugs (including therapeutic monoclonal antibody drugs), gene therapy/cell therapy drugs, and chemical drugs. The treatment field covers various fields such as nervous system related diseases, infectious diseases, gastrointestinal diseases, urinary system diseases, and autoimmune diseases. The company has independently developed a national first class new drug - the injection of mouse nerve growth factor "Supeptidase" and the only intestinal and constipation clearing drug in China with two indications - polyethylene glycol electrolyte powder "Shutaiqing". The company's main products have been recognized as "National Torch Program Products", "Beijing High tech Achievement Transformation Project", "National Biomedical High tech Industrialization Demonstration Project", and "Beijing Independent Innovation Products", and have won the third prize of Beijing Science and Technology Progress Award. |
| Headquarter | Beijing |
| Establish Date | 8/16/2002 |
| Listed Code | 300204.SZ |
| Listed Date | 4/15/2011 |
| Chairman | Zhou Zhiwen. |
| CEO | Wang Chao. |
| Website | www.staidson.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
